
SIL-TAL1 fusion gene negative impact in T-cell acute lymphoblastic leukemia outcome
2009; Taylor & Francis; Volume: 50; Issue: 8 Linguagem: Inglês
10.1080/10428190903040014
ISSN1042-8194
AutoresMarcela Braga Mansur, Mariana Emerenciano, Lilian Brewer, Mariana Oliveira Santana, Núbia Mendonça, Luiz Cláudio Santos Thuler, Sérgio Koifman, Maria S. Pombo‐de‐Oliveira,
Tópico(s)Chronic Myeloid Leukemia Treatments
ResumoSIL-TAL1 fusion gene and the ectopic expression of HOX11L2 are common molecular abnormalities in T-cell acute lymphoblastic leukemia (T-ALL). To verify their influence on outcome, we analyzed a Brazilian pediatric T-ALL series of cases. One hundred and ninety two children, age ranged 0–21 years old, were consecutively diagnosed and treated. Reverse transcriptase-polymerase chain reaction (RT-PCR) technique was used to identify the molecular alterations. Kaplan–Meyer method was applied to estimate overall survival. The most frequent maturation stage was T-IV (40.1%), and 30.7% of cases were CD10+. SIL-TAL1+ and HOX11L2+ accounted for 26.7% and 10.3% of the cases, respectively. The overall survival (OS) was 74% in 80-month follow-up. HOX11L2+ was not predictive factor for outcome. Considering patients younger than nine years-old, those with SIL-TAL1+ presented a poorer outcome (p = 0.02). The results of this study suggest that in the Brazilian population only the presence of SIL-TAL1 can predict outcome in a restricted group of patients.
Referência(s)